Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report

Abstract

Background

Non-response to first-line treatment for major depressive disorder (MDD) is common; for such individuals, quality of life (QoL) impairments can be severe. Identifying predictors of QoL changes may support the management of cases with persistent depressive symptoms despite adequate initial pharmacological/psychological treatment.

Objective

The present study aimed to explore predictors of domain-specific QoL improvement following adjunctive aripiprazole treatment for inadequate response to initial antidepressant therapy.

Methods

We evaluated secondary QoL outcomes from a CAN-BIND (Canadian Biomarker Integration Network in Depression) study in patients with MDD who did not respond to an initial 8 weeks of escitalopram and received a further 8 weeks of adjunctive aripiprazole (n = 96). Physical, psychological, social, and environmental QoL domains were assessed using the World Health Organization QoL Scale Brief Version (WHOQOL-BREF). Clinician-rated depressive symptoms were assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS). Functioning was measured with the Sheehan Disability Scale (SDS). Satisfaction with medication was assessed with a single item from the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). Exploratory t-tests were used to describe domain score changes. A hierarchical linear regression was used to explore demographic, clinical, and treatment-related predictors of improvement.

Results

Across domains, QoL improved with adjunctive aripiprazole treatment. Satisfaction with medication and MADRS and SDS scores similarly improved. Symptom reduction was a predictor for positive change to physical and psychological QoL; functioning improvements were predictive of increases to all QoL domains. Satisfaction with medication predicted improvements to physical and psychological domains, whereas number of medication trials was a predictor of worsening QoL in the physical domain.

Conclusion

The final model explained the most variance in psychological (68%) and physical (67%) QoL. Less variance was explained for environmental (43%) and social QoL (33%), highlighting a need for further exploration of predictors in these domains. Strategies such as functional remediation may have potential to support QoL for individuals with persistent depressive symptoms.

Clinical Trials Registry

ClinicalTrials.gov identifier: NCT016557.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43:471–81.

    CAS  PubMed  Google Scholar 

  2. 2.

    Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T, et al. The prevalence and burden of bipolar disorder: Findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18:440–50.

    PubMed  Google Scholar 

  3. 3.

    Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntyre RS. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry. 2012;24:82–90.

    PubMed  Google Scholar 

  4. 4.

    Plaisier I, Beekman AT, de Graaf R, Smit JH, van Dyck R, Penninx BW. Work functioning in persons with depressive and anxiety disorders: the role of specific psychopathological characteristics. J Affect Disord. 2010;125:198–206.

    CAS  PubMed  Google Scholar 

  5. 5.

    Beck A, Crain AL, Solberg LI, Unützer J, Glasgow RE, Maciosek MV, et al. Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011;9:305–11.

    PubMed  PubMed Central  Google Scholar 

  6. 6.

    Kupferberg A, Bicks L, Hasler G. Social functioning in major depressive disorder. Neurosci Biobehav Rev. 2016;69:313–32.

    PubMed  Google Scholar 

  7. 7.

    Visentini C, Cassidy M, Bird VJ, Priebe S. Social networks of patients with chronic depression: a systematic review. J Affect Disord. 2018;241:571–8.

    PubMed  Google Scholar 

  8. 8.

    Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163:148–50.

    PubMed  Google Scholar 

  9. 9.

    Rosenblat JD, Simon GE, Sachs GS, Deetz I, Doederlein A, DePeralta D, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2019;243:116–20.

    PubMed  Google Scholar 

  10. 10.

    The WHOQOL Group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403–9.

    Google Scholar 

  11. 11.

    Measuring success: the problem with primary outcomes. Lancet Psychiatry. 2020;7:1. https://doi.org/10.1016/S2215-0366(19)30483-3

  12. 12.

    Mauskopf JA, Simon GE, Kalsekar A, Nimsch C, Dunayevich E, Cameron A. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety. 2009;26:83–97.

    PubMed  Google Scholar 

  13. 13.

    Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195–210.

    PubMed  Google Scholar 

  14. 14.

    Dennehy EB, Marangell LB, Martinez J, Balasubramani GK, Wisniewski SR. Clinical and functional outcomes of patients who experience partial response to citalopram: Secondary analysis of STAR*D. J Psychiatr Pract. 2014;20:178–87.

    PubMed  Google Scholar 

  15. 15.

    Kolovos S, van Tulder MW, Cuijpers P, Prigent A, Chevreul K, Riper H, et al. The effect of treatment as usual on major depressive disorder: a meta-analysis. J Affect Disord. 2017;210:72–81.

    PubMed  Google Scholar 

  16. 16.

    Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SRJCpr. The STAR* D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449-59.

  17. 17.

    Ishak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord. 2013;151:59–65.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Solomon DA, Leon AC, Endicott J, Mueller TI, Coryell W, Shea MT, et al. Psychosocial impairment and recurrence of major depression. Compr Psychiatry. 2004;45:423–30.

    PubMed  Google Scholar 

  19. 19.

    Kuehner C, Huffziger S. Subjective quality of life aspects predict depressive symptoms over time: results from a three-wave longitudinal study. Acta Psychiatr Scand. 2009;120:496–9.

    CAS  PubMed  Google Scholar 

  20. 20.

    Jha MK, Greer TL, Grannemann BD, Carmody T, Rush AJ, Trivedi MH. Early normalization of Quality of Life predicts later remission in depression: findings from the CO-MED trial. J Affect Disord. 2016;206:17–22.

    PubMed  Google Scholar 

  21. 21.

    Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61:540–60.

    PubMed  PubMed Central  Google Scholar 

  22. 22.

    Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29:459–525.

    CAS  PubMed  Google Scholar 

  23. 23.

    Pae C-U, Patkar AA. Clinical issues in use of atypical antipsychotics for depressed patients. CNS Drugs. 2013;27:39–45.

    Google Scholar 

  24. 24.

    Knoth RL, Bolge SC, Kim E, Tran QV. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16:e188–96.

    PubMed  Google Scholar 

  25. 25.

    Trivedi MH, Morris DW, Wisniewski SR, Lesser I, Nierenberg AA, Daly E, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013;170:633–41.

    PubMed  Google Scholar 

  26. 26.

    Kamenov K, Twomey C, Cabello M, Prina AM, Ayuso-Mateos JL. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychol Med. 2016;47:414–25.

    PubMed  PubMed Central  Google Scholar 

  27. 27.

    Morton E, Michalak EE, Levitt A, Levitan RD, Cheung A, Morehouse R, et al. Quality of life impacts of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: A randomized clinical trial. Can J Psychiatry. 2020:0706743720936470.

  28. 28.

    IsHak WW, Mirocha J, James D, Tobia G, Vilhauer J, Fakhry H, et al. Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. Acta Psychiatr Scand. 2015;131:51–60.

    CAS  PubMed  Google Scholar 

  29. 29.

    Ishak WW, Balayan K, Bresee C, Greenberg JM, Fakhry H, Christensen S, et al. A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting. Qual Life Res. 2013;22:585–96.

    PubMed  Google Scholar 

  30. 30.

    Cohen RM, Greenberg JM, IsHak WW. Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the individual burden of illness index for depression to measure treatment impact and recovery in MDD. JAMA Psychiatry. 2013;70:343–50.

    PubMed  Google Scholar 

  31. 31.

    Berlim MT, McGirr A, Fleck MP. Can sociodemographic and clinical variables predict the quality of life of outpatients with major depression? Psychiatry Res. 2008;160:364–71.

    PubMed  Google Scholar 

  32. 32.

    Berlim MT, Pargendler J, Brenner J, Fleck MP. Significant improvement in the quality of life of Brazilian depressed outpatients 12 weeks following the start of antidepressants. Psychiatry Res. 2007;153:253–9.

    CAS  PubMed  Google Scholar 

  33. 33.

    Lex H, Ginsburg Y, Sitzmann AF, Grayhack C, Maixner DF, Mickey BJ. Quality of life across domains among individuals with treatment-resistant depression. J Affect Disord. 2019;243:401–7.

    PubMed  Google Scholar 

  34. 34.

    Kennedy SH, Lam RW, Rotzinger S, Milev RV, Blier P, Downar J, et al. Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: a CAN-BIND-1 report. J Clin Psychiatry. 2019;80(2):18m12202.

  35. 35.

    Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, et al. Discovering biomarkers for antidepressant response: Protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry. 2016;16:105.

    PubMed  PubMed Central  Google Scholar 

  36. 36.

    Stevanovic D. Quality of Life Enjoyment and Satisfaction Questionnaire—short form for quality of life assessments in clinical practice: A psychometric study. J Psychiatr Ment Health Nurs. 2011;18:744–50.

    CAS  PubMed  Google Scholar 

  37. 37.

    Kalsekar I, Wagner JS, DiBonaventura M, Bates J, Forbes R, Hebden T. Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey. Health Qual Life Outcomes. 2012;10:81.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, et al. Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. Neuropsychiatr Dis Treat. 2018;14:103–15.

    CAS  PubMed  Google Scholar 

  39. 39.

    Morton E, Bhat V, Giacobbe P, Lou W, Michalak E, Chakrabarty T, et al. (In press). Impacts on quality of life with escitalopram monotherapy and aripiprazole augmentation in patients with major depressive disorder: a CAN-BIND report. Pharmacopsychiatry.

  40. 40.

    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.

    CAS  PubMed  Google Scholar 

  41. 41.

    Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22-33.

  42. 42.

    Vaccarino AL, Dharsee M, Strother S, Aldridge D, Arnott SR, Behan B, et al. Brain-CODE: a secure neuroinformatics platform for management, federation, sharing and analysis of multi-dimensional neuroscience data. Front Neuroinform. 2018;12:28.

    PubMed  PubMed Central  Google Scholar 

  43. 43.

    World Health Organization. WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment: field trial version, December 1996: Geneva: World Health Organization; 1996.

  44. 44.

    Oliveira SEH, Carvalho H, Esteves F. Toward an understanding of the quality of life construct: validity and reliability of the WHOQOL-BREF in a psychiatric sample. Psychiatry Res. 2016;244:37–44.

    PubMed  Google Scholar 

  45. 45.

    Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27:93–105.

    CAS  PubMed  Google Scholar 

  46. 46.

    Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192:52–8.

    PubMed  Google Scholar 

  47. 47.

    Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62:10–7.

    CAS  PubMed  Google Scholar 

  48. 48.

    European Medicines Agency (EMA). Guideline on missing data in confirmatory clinical trials. 2011. CPMP/EWP/1776/99 CPMP/EWP/1776/99.

  49. 49.

    Cohen J, Cohen R, Adad J, Cohen J, Cohen J, Mansfield J, et al. Statistical power analysis for the behavioral sciences. J Am Stat Assoc. 1988;84:1096–7.

    Google Scholar 

  50. 50.

    Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–6.

    CAS  PubMed  Google Scholar 

  51. 51.

    Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007;52:46–54.

    PubMed  Google Scholar 

  52. 52.

    Berlim MT, Pavanello DP, Caldieraro MAK, Fleck MPA. Reliability and validity of the WHOQOL BREF in a sample of Brazilian outpatients with major depression. Qual Life Res. 2005;14:561–4.

    PubMed  Google Scholar 

  53. 53.

    Naumann VJ, Byrne GJ. WHOQOL-BREF as a measure of quality of life in older patients with depression. Int Psychogeriatr. 2004;16:159–73.

    PubMed  Google Scholar 

  54. 54.

    da Rocha NS, Power MJ, Bushnell DM, Fleck MP. Is there a measurement overlap between depressive symptoms and quality of life? Compr Psychiatry. 2009;50:549–55.

    PubMed  Google Scholar 

  55. 55.

    Skevington SM, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299–310.

    CAS  PubMed  Google Scholar 

  56. 56.

    Bo Q, Tian L, Li F, Mao Z, Wang Z, Ma X, et al. Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder. Neuropsychiatr Dis Treat. 2019;15:1649–57.

    PubMed  PubMed Central  Google Scholar 

  57. 57.

    Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive brexpiprazole and functioning in major depressive disorder: a pooled analysis of six randomized studies using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019;22:173–9.

    CAS  PubMed  Google Scholar 

  58. 58.

    Pan A-W, Chen Y-L, Chung L-I, Wang J-D, Chen T-J, Hsiung P-C. A longitudinal study of the predictors of quality of life in patients with major depressive disorder utilizing a linear mixed effect model. Psychiatry Res. 2012;198:412–9.

    PubMed  Google Scholar 

  59. 59.

    IsHak WW, Greenberg JM, Balayan K, Kapitanski N, Jeffrey J, Fathy H, et al. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011;19:229–39.

    PubMed  Google Scholar 

  60. 60.

    Bowling A. Current state of the art in quality of life measurement. In: Carr AJ, Higginson I, Robinson PG, editors. Quality of Life. London: BMJ Books; 2008. p. 1–8.

    Google Scholar 

  61. 61.

    Bowling A. Measuring disease: a review of disease-specific quality of life measurements. 2nd ed. Philadelphia: Open University Press; 2001.

    Google Scholar 

  62. 62.

    Lam RW, Parikh SV, Michalak EE, Dewa CS, Kennedy SH. Canadian etwork for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry. 2015;27:142–9.

    PubMed  Google Scholar 

  63. 63.

    Ishak WW, Greenberg JM, Saah T, Mobaraki S, Fakhry H, Wu QV, et al. Development and validation of the Individual Burden of Illness Index for Major Depressive Disorder (IBI-D). Adm Policy Ment Health. 2013;40:76–86.

    PubMed  PubMed Central  Google Scholar 

  64. 64.

    Pyne JM, Sieber WJ, David K, Kaplan RM, Hyman Rapaport M, Keith WD. Use of the Quality of Well-Being Self-Administered version (QWB-SA) in assessing health-related quality of life in depressed patients. J Affect Disord. 2003;76:237–47.

    PubMed  Google Scholar 

  65. 65.

    Daly EJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Gaynes BN, Warden D, et al. Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry. 2010;22:43–55.

    PubMed  Google Scholar 

  66. 66.

    Bowie CR, Gupta M, Holshausen K, Jokic R, Best M, Milev RJ, Jon T, et al. Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. J Nerv Ment Dis. 2013;201:680–5.

    PubMed  Google Scholar 

  67. 67.

    Siskind D, Harris M, Pirkis J, Whiteford H. Personalised support delivered by support workers for people with severe and persistent mental illness: a systematic review of patient outcomes. Epidemiol Psychiatr Sci. 2012;21:97–110.

    CAS  PubMed  Google Scholar 

  68. 68.

    Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. World Psychiatry. 2016;15(3):288–9.

    PubMed  PubMed Central  Google Scholar 

  69. 69.

    Duckworth AL, Tsukayama E, May H. Establishing causality using longitudinal hierarchical linear modeling: an illustration predicting achievement from self-control. Soc Psychol Personal Sci. 2010;1(4):311–7.

    PubMed  PubMed Central  Google Scholar 

  70. 70.

    Bauer D, Preacher K, Gil K. Conceptualizing and testing random indirect effects and moderated mediation in multilevel models: new procedures and recommendations. Psychol Methods. 2006;11:142–63.

    PubMed  Google Scholar 

  71. 71.

    Endicott J, Lam RW, Hsu MA, Fayyad R, Boucher M, Guico-Pabia CJ. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder. J Affect Disord. 2014;166:307–14.

    CAS  PubMed  Google Scholar 

  72. 72.

    Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–33.

    PubMed  Google Scholar 

  73. 73.

    Morton E, Michalak EE, Murray G. What does quality of life refer to in bipolar disorders research? A systematic review of the construct’s definition, usage and measurement. J Affect Disord. 2017;212:128–37.

    PubMed  Google Scholar 

  74. 74.

    Yen C-F, Chen C-C, Lee Y, Tang T-C, Ko C-H, Yen J-Y. Association between quality of life and self-stigma, insight, and adverse effects of medication in patients with depressive disorders. Depress Anxiety. 2009;26:1033–9.

    PubMed  Google Scholar 

  75. 75.

    da Silva Lima AFB, de Almeida Fleck MP. Subsyndromal depression: an impact on quality of life? J Affect Disord. 2007;100:163–9.

    PubMed  Google Scholar 

  76. 76.

    Kuehner C, Buerger C. Determinants of subjective quality of life in depressed patients: the role of self-esteem, response styles, and social support. J Affect Disord. 2005;86:205–13.

    PubMed  Google Scholar 

  77. 77.

    Trompenaars FJ, Masthoff ED, Van Heck GL, Hodiamont PP, De Vries J. Relationships between demographic variables and quality of life in a population of Dutch adult psychiatric outpatients. Soc Psychiatry Psychiatr Epidemiol. 2005;40:588–94.

    PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to Emma Morton.

Ethics declarations

Author contributions

EM conceptualized and conducted the statistical analysis and drafted the manuscript. SHK, RWL, RVM, SR, PG, SM, BNF, SVP, DJM, VB, WL, EEM, and TC made substantial contributions to overall study conception and design and to ongoing data collection and analysis. All authors provided critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Funding

CAN-BIND is an Integrated Discovery Programme that is carried out in partnership with, and receives financial support from, the Ontario Brain Institute, an independent non-profit corporation funded partially by the Ontario government. The opinions, results and conclusions are those of the authors, and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding was provided by the Canadian Institutes of Health Research, Lundbeck, Bristol Myers Squibb, and Servier. Funding and/or in-kind support was also provided by the investigators’ academic institutions. Emma Morton was supported by a postdoctoral award from the Marshall Scholars and Fellows Programme in Mental Health, Institute of Mental Health, University of British Columbia, Canada. Venkat Bhat was supported by an Academic Scholar Award from the Department of Psychiatry at the University of Toronto.

Conflict of interest

Emma Morton, Venkat Bhat, Wendy Lou, Trisha Chakrabarty, and Daniel J. Müller have no conflicts of interest that are directly relevant to the content of this article. Peter Giacobbe has received research support from the Academic Scholar’s Award, University of Toronto Department of Psychiatry, CIHR, PSI, and Veteran's Affairs Canada; served on an advisory board for Janssen; and been an unpaid consultant for St. Jude Medical. Erin E. Michalak has received funding from Otsuka to support patient education initiatives. Shane McInerney has received advisory panel income from Janssen and research grant funding through the Healthy Minds Canada/Pfizer Canada Workplace Depression Awards. Benicio N. Frey has received a research grant from Pfizer outside of this work. Roumen V. Milev has received consulting and speaking honoraria from AbbVie, Allergan, Janssen, KYE, Lundbeck, Otsuka, and Sunovion and research grants from CAN-BIND, CIHR, Janssen, Lallemand, Lundbeck, Nubiyota, OBI, and OMHF. Sagar V. Parikh has received honoraria or research funds from Assurex, Takeda, Janssen, Mensante, Aifred, and Sage. Susan Rotzinger holds a patent ‘Teneurin C-Terminal Associated Peptides (TCAP) and methods and uses thereof.’ (inventors: David Lovejoy, R.B. Chewpoy, Dalia Barsyte, and Susan Rotzinger). Sidney H. Kennedy has received honoraria or research funds from Abbott, Alkermes, Allergan, Boehringer Ingelheim, Brain Canada, CIHR, Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund, Otsuka, Pfizer, Servier, Sunovion, and Sun Pharmaceuticals and holds stock in Field Trip Health. Raymond W. Lam has received honoraria or research funds from Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, CIHR, CANMAT, Canadian Psychiatric Association, Hansoh, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, MITACS, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Pfizer, St. Jude Medical, University Health Network Foundation, and the VGH-UBC Hospital Foundation.

Ethics approval

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Consent for publication

All participants provided written, informed consent.

Availability of data and material

Data are not publicly available in accordance with ethics approval given by the ethics board from the participating university. Interested investigators may submit inquiries to the corresponding author.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Morton, E., Bhat, V., Giacobbe, P. et al. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. CNS Drugs 35, 439–450 (2021). https://doi.org/10.1007/s40263-021-00803-2

Download citation